BioCentury | Jun 27, 2020
Product Development

A mechanistic view of four compounds that disrupt interleukin pathways to treat severe COVID-19

...Actemra (Informal) Kevzara (Brand), SAR153191 (Compound #), REGN88 (Compound #), sarilumab (Generic) Interleukin-1 (IL-1) Interleukin-6 (IL-6) Interleukin-6 (IL-6) receptor (CD126) Interleukin-1 (IL-1) alpha Interleukin-1...
BioCentury | Dec 10, 2019
Company News

Janssen pays $750M for XBiotech's dermatology candidate after positive Phase II data

...make XBiotech profitable or near-profitable over the next two years, Simard said. Targets: IL-1α - Interleukin-1 alpha...
...Interleukin-4 receptor; TNFα - Tumor necrosis factor alpha Elizabeth S. Eaton, Staff Writer Janssen Johnson & Johnson XBiotech Inc. Interleukin-1 (IL-1) alpha...
BioCentury | Oct 8, 2019

Inhibiting caspase-mediated pyroptosis for graft-versus-host disease

...doi:10.1038/s41467-019-11895-2 CONTACT: Ben Lu, Central South University, Changsha, China email: xybenlu@csu.edu.cn Claire Quang Central South University Gasdermin D (GSDMD) Interleukin-1 (IL-1) alpha Lipopolysaccharide...
BioCentury | Feb 7, 2018
Distillery Therapeutics

Cancer

...Columbia, S.C. email: hchen@biol.sc.edu Hongjiang Li University of South Carolina Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Interleukin-1 (IL-1) alpha Interleukin-6...
BioCentury | Sep 22, 2017
Clinical News

CHMP reiterates negative opinion on XBiotech's Hutruo

...Xilonix , CV-18C3 , T2-18C3 , RA-18C3 , MABp1 , CA-18C3) Business: Cancer Jennie Walters CA-18C3 CV-18C3 Hutruo MABp1 RA-18C3 T2-18C3 Xilonix XBiotech Inc. Interleukin-1 (IL-1) alpha...
BioCentury | Jun 16, 2017
Clinical News

XBiotech discontinues Xilonix CRC trial

...survival (PFS) and objective response rate (ORR) Status: Phase III discontinued Milestone: NA Jaime De Leon CA-18C3 CV-18C3 Hutruo MABp1 RA-18C3 T2-18C3 Xilonix XBiotech Inc. Interleukin-1 (IL-1) alpha...
BioCentury | Jun 9, 2017
Clinical News

XBiotech sags after discontinuing Xilonix CRC study

...alpha, which is called Hutruo in Europe (see BioCentury Extra, April 21) . Jaime De Leon CA-18C3 CV-18C3 Hutruo MABp1 RA-18C3 T2-18C3 Xilonix XBiotech Inc. Interleukin-1 (IL-1) alpha...
BioCentury | May 25, 2017
Clinical News

CHMP recommends against XBiotech's colorectal cancer candidate

...Hutruo , CV-18C3 , T2-18C3 , RA-18C3 , MABp1 , CA-18C3) Business: Cancer Alex Himes CA-18C3 CV-18C3 Hutruo MABp1 RA-18C3 T2-18C3 Xilonix XBiotech Inc. Interleukin-1 (IL-1) alpha...
BioCentury | May 19, 2017
Company News

CHMP backs approval of Veltassa, other candidates

...April 21) . Chris Lieu brodalumab cariprazine Veltassa Xilonix Gedeon Richter Ltd. Leo Pharma A/S Sanofi Vifor Pharma Ltd. XBiotech Inc. Dopamine D2 receptor Dopamine D3 receptor (DRD3) Interleukin-1 (IL-1) alpha Interleukin-17...
BioCentury | Apr 28, 2017
Clinical News

Hutruo regulatory update

...Hutruo , CV-18C3 , T2-18C3 , RA-18C3 , MABp1 , CA-18C3) Business: Cancer Jaime De Leon CA-18C3 CV-18C3 MABp1 RA-18C3 T2-18C3 Xilonix XBiotech Inc. Interleukin-1 (IL-1) alpha Hutruo...
Items per page:
1 - 10 of 32